Table 1 Baseline characteristics of patients (TCGA-UCEC).

Clinical stage, n (%)

Stage I

194 (70.3%)

148 (53.6%)

< 0.001

Stage II

27 (9.8%)

24 (8.7%)

Stage III

47 (17%)

83 (30.1%)

Stage IV

8 (2.9%)

21 (7.6%)

Primary therapy outcome, n (%)

PD

10 (4%)

10 (4.3%)

0.001

SD

3 (1.2%)

3 (1.3%)

PR

0 (0%)

12 (5.2%)

CR

236 (94.8%)

206 (89.2%)

Weight, n (%)

<=80

97 (36.6%)

146 (55.5%)

< 0.001

>80

168 (63.4%)

117 (44.5%)

Height, n (%)

<=160

109 (41.6%)

138 (52.9%)

0.013

>160

153 (58.4%)

123 (47.1%)

BMI, n (%)

<=30

89 (34.2%)

123 (47.5%)

0.003

>30

171 (65.8%)

136 (52.5%)

Histological type, n (%)

Endometrioid

237 (85.9%)

173 (62.7%)

< 0.001

Mixed

9 (3.3%)

15 (5.4%)

Serous

30 (10.9%)

88 (31.9%)

Histologic grade, n (%)

G1

73 (26.8%)

25 (9.3%)

< 0.001

G2

83 (30.5%)

37 (13.8%)

G3

116 (42.6%)

207 (77%)

Age, n (%)

<=60

109 (39.6%)

97 (35.4%)

0.349

>60

166 (60.4%)

177 (64.6%)

Residual tumor, n (%)

R0

199 (93.4%)

176 (88%)

0.075

R1

10 (4.7%)

12 (6%)

R2

4 (1.9%)

12 (6%)

Tumor invasion, n (%)

<50

143 (56.7%)

116 (52.3%)

0.374

>=50

109 (43.3%)

106 (47.7%)

Menopause status, n (%)

Pre

16 (6.3%)

19 (7.5%)

0.186

Peri

5 (2%)

12 (4.7%)

Post

232 (91.7%)

222 (87.7%)

Hormones therapy, n (%)

No

158 (88.3%)

139 (84.2%)

0.353

Yes

21 (11.7%)

26 (15.8%)

Diabetes, n (%)

No

165 (72.1%)

163 (73.4%)

0.825

Yes

64 (27.9%)

59 (26.6%)

Radiation therapy, n (%)

No

147 (54.9%)

132 (51%)

0.420

Yes

121 (45.1%)

127 (49%)

Surgical approach, n (%)

Minimally Invasive

98 (36.4%)

110 (42.1%)

0.208

open

171 (63.6%)

151 (57.9%)

Race, n (%)

Asian

13 (5.1%)

7 (2.8%)

0.100

Black or African American

46 (18%)

62 (24.6%)

White

196 (76.9%)

183 (72.6%)